GENFIT-ADR (GNFT) Stock Fundamental Analysis

NASDAQ:GNFT • US3722791098

4.85 USD
+0.12 (+2.54%)
Last: Nov 19, 2025, 02:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall GNFT gets a fundamental rating of 2 out of 10. We evaluated GNFT against 523 industry peers in the Biotechnology industry. Both the profitability and financial health of GNFT have multiple concerns. GNFT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year GNFT has reported negative net income.
  • GNFT had a negative operating cash flow in the past year.
  • In multiple years GNFT reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
GNFT Yearly Net Income VS EBIT VS OCF VS FCFGNFT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • GNFT has a better Return On Assets (-17.89%) than 78.13% of its industry peers.
  • With a Return On Equity value of -73.87%, GNFT perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
Industry RankSector Rank
ROA -17.89%
ROE -73.87%
ROIC N/A
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNFT Yearly ROA, ROE, ROICGNFT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • GNFT's Profit Margin has declined in the last couple of years.
  • In the last couple of years the Operating Margin of GNFT has declined.
  • GNFT's Gross Margin of 95.42% is amongst the best of the industry. GNFT outperforms 94.95% of its industry peers.
  • In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
  • GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.42%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
GNFT Yearly Profit, Operating, Gross MarginsGNFT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GNFT has more shares outstanding than it did 1 year ago.
  • GNFT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, GNFT has a worse debt to assets ratio.
GNFT Yearly Shares OutstandingGNFT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GNFT Yearly Total Debt VS Total AssetsGNFT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • GNFT has an Altman-Z score of -1.41. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
  • GNFT has a Altman-Z score (-1.41) which is comparable to the rest of the industry.
  • GNFT has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • GNFT has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: GNFT underperforms 63.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.41
ROIC/WACCN/A
WACC7.22%
GNFT Yearly LT Debt VS Equity VS FCFGNFT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
  • GNFT has a Current ratio of 3.74. This is comparable to the rest of the industry: GNFT outperforms 44.67% of its industry peers.
  • A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
  • GNFT has a Quick ratio (3.74) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
GNFT Yearly Current Assets VS Current LiabilitesGNFT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for GNFT have decreased strongly by -289.19% in the last year.
  • GNFT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -70.77% yearly.
  • GNFT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -45.94%.
  • Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%

3.2 Future

  • The Earnings Per Share is expected to decrease by -29.44% on average over the next years. This is quite bad
  • GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.86% yearly.
EPS Next Y-192.65%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue Next Year-34.41%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GNFT Yearly Revenue VS EstimatesGNFT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
GNFT Yearly EPS VS EstimatesGNFT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • GNFT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNFT Price Earnings VS Forward Price EarningsGNFT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNFT Per share dataGNFT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • GNFT's earnings are expected to decrease with -45.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GNFT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GENFIT-ADR

NASDAQ:GNFT (11/19/2025, 2:00:00 PM)

4.85

+0.12 (+2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)04-22
Inst Owners0.73%
Inst Owner Change-12.22%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap242.51M
Revenue(TTM)45.41M
Net Income(TTM)-38.76M
Analysts90.77
Price Target9.84 (102.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.43%
PT rev (3m)-8.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-766.16%
EPS NY rev (3m)-159.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.49%
Revenue NY rev (3m)-29.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.59
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 97.96
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS1.06
BVpS1.22
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.89%
ROE -73.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.42%
FCFM N/A
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.46%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -1.41
F-Score2
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-192.65%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-34.41%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-284.52%
EBIT Next 3Y-33.99%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A

GENFIT-ADR / GNFT FAQ

What is the fundamental rating for GNFT stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNFT.


What is the valuation status for GNFT stock?

ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.


Can you provide the profitability details for GENFIT-ADR?

GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.


What is the expected EPS growth for GENFIT-ADR (GNFT) stock?

The Earnings per Share (EPS) of GENFIT-ADR (GNFT) is expected to decline by -192.65% in the next year.